Connect with us

BenzingaEditorial

Reinventing Vaccines to Save Lives and the Economy

Published

on

Vaccine News

Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) were the first to deliver good news regarding efficiency of their coronavirus vaccine candidate. Moderna (NASDAQ:MRNA) had its turn last week, delivering even better news, with US stocks hitting a new record. This Monday, stocks also rejoiced as the University of Oxford and AstraZeneca (NASDAQ: AZN) delivered the third major breakthrough in stopping people from developing Covid-19 symptoms. A process that usually takes a decade was shortened to just 10 months, with drugmakers providing a glimpse of light at the end of the global pandemic tunnel.

mRNA vaccines by Pfizer & BioNTech and Moderna

Last week, Pfizer announced that early data show its vaccine is more than 90% effective. Moderna went a step further as it revealed 94.5% effectiveness of its candidate, making it the second vaccine in the US to have a stunningly high success rate. Both companies reported that there were no serious side effects with only a small percentage of participants experiencing mild ache symptoms such as headaches.

Pfizer’s and Moderna’s vaccines have similar results because they use the same technique to activate the body’s immune system as they inject the virus’s genetic code for the immune system to create antibodies. This genetic code is the messenger RNA, or mRNA that mimics what the virus does without causing the disease. If a vaccinated person is later actually exposed to the coronavirus, those antibodies should be ready to attack and defend. Although this new technology is not found in any vaccine currently on the market, these impressive results seen in both trials seem to validate its efficiency.

Similarities and differences

Both vaccines need to be taken in two doses. Besides the identical dosage, they have a similar rate of protection and safety. But, Moderna has the lead due to two significant advantages over Pfizer. Unlike any other vaccine in the US, Pfizer’s vaccine has to be kept at minus 75 degrees Celsius, whereas Moderna requires only 20 degrees Celsius. Doctors’ offices and pharmacies do not have freezers to store Pfizer’s vaccine. The second advantage is the expiration date, as Moderna’s can be kept for 30 days whereas Pfizer’s can only last five days.

A viral-vectored vaccine by Astrazeneca

Astrazeneca and Oxford University’s candidate demonstrated efficacy of 70.4% in two large-scale trails. Most importantly, nobody who received the actual vaccine developed any severe symptoms or needed hospital treatment. If a lower dose is used, followed by a second, full dose, the efficacy is up to 90%.

Despite being less than Pfizer and Moderna’s protection level, Oxford’s candidate is far cheaper, and is easier to store and distribute across the globe, if it gets approved. However, AstraZeneca’s stock tumbled after Wall Street analyst Geoffrey Porges raised questions about whether it would receive U.S. regulatory approval. But Oxford technology is more established, so the vaccine is easier to mass produce cheaply which can play a significant role in tackling the pandemic.

A traditional approach

This candidate uses a traditional approach that is completely different from that of Pfizer and Moderna. A viral-vectored vaccine uses an adenovirus, a common cold virus, that has been genetically modified to include genetic material from the SARS-CoV-2 virus. With a purified signature protein of the virus that is much weaker than the ‘original’, it trains the immune system to recognize the disease-causing part of a virus. Therefore, if the immune system actually comes into contact with the virus, it will know exactly what to do. This approach prevents the patient from developing severe symptoms, complications and hospital treatment.

Why the low dose first? There are two answers. One is that if the initial dose is too big, the immune system might reject the vaccine which is built around a common cold virus. The other is that a low then high shot may do a better job at mimicking an actual coronavirus infection and therefore, lead to a better immune response.

The ‘contest’

After Pfizer and Moderna’s above 90% protection, 70% might be seen as disappointing. But this is still a vaccine that can save lives and play a role in containing the pandemic. It also has crucial advantages such as a more convenient storage and a smaller price. As AstraZeneca has also made a “no-profit pledge”, its candidate will cost about $4, which is far less than Pfizer’s $20 and especially Moderna’s $37 per dose.

Too early to claim victory

The FDA requires two months of follow-up data when vaccine developers submit the application for emergency use. Most side-effects appear within 60 days of receiving the vaccine so this is a necessary safety measure. But it does not mean that rare issues canot crop up later. The risk is even greater for mRNA candidates as they will be the first to use this technology. This means the FDA will need to weigh the potential benefits over the known risks before granting emergency use authorization. We all need to accept that there will be risks but the FDA has the hard task of finding the balance between taming the pandemic as soon as possible and having the perfect data. Meanwhile, the U.S. is all set to roll out Regeneron (NASDAQ: REGN) antibody cocktail. Therefore, positive developments are there, but the battle is far from over as all three vaccines still need to prove they are safe.

This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure . IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you’re interested in becoming an IAM journalist contact: contributors@iamnewswire.com

BenzingaEditorial

BMW, XPENG and Worksport Switching Gears Forward

Published

on

The EV revolution is happening with governments and automakers going full speed ahead to combat carbon emissions with all-electric vehicles. Many players joining forces in the attempt to win the race with the power of synergy. Even the almighty Toyota Motor (NYSE: TM) knew better than going at it alone as it partnered with Panasonic Corporation (OTC: PCRFY) to form Prime Planet Energy & Solutions to develop batteries that can be used over and over again anytime, anywhere. In June, Renault SA (OTC: RNLSY) revealed it formed two major partnerships to specialize in the design and production of EV batteries. In March, Volkswagen (OTC: VWAGY) announced it aims to build several “gigafactories” in Europe by 2030. This week, we got a few more expansion updates.

BMW receives battery ‘fuel’

Bayerische Motoren Werke Aktiengesellschaft (OTC: BMWYY) is also working on new concepts and ideas related to batteries.  Its project BMW-UK-BEV that is centered around the development of a long-distance EV battery has been awarded $36.07 million in joint funding from the industry and the U.K. government. The U.K. is determined to stop selling new diesel and gasoline cars and vans by 2030, the Oxford-based project is one of four to receive funding as new technologies that address range anxiety are crucial to wider EV adoption.

XPeng is is quadrupling capacity

The Chinese EV maker announced it will quadruple capacity as it signed an agreement with a Zhaoqing Smart EV Manufacturing Base expansion project that will boost capacity to 200,000 units annually from 100,000 units. The expansion will enable Xpeng Inc (NYSE: XPEV) to capture the anticipated increase in consumer demand for its smart EVs. In addition to Zhaoqing, XPeng is building manufacturing capacity in Guangzhou and Wuhan, which should enable it to make 400,000 EVs a year, four times what it produces today.

XPeng has delivered about 58,000 vehicles over the past 12 months, behind 76,000 vehicles from NIO Inc (NYSE: NIO) and 59,000 by Li Auto Inc (NASDAQ: LI).

All these three U.S.-listed Chinese EVs are expanding production to meet rising demand. Nio recently announced it will more than double its current production of 100,000 vehicles to 240,000 units a year. Li Auto raised more money in August selling stock in Hong Kong, part of which will commit to doubling capacity to 200,000 units a year.

Worksport announcing Pre-Order Date Solar Covers

Worksport moved into its new headquarters and 55,000 sqaure feet manufacturing facility. As its tonneau cover business continues to grow, Worksport Ltd (NASDAQ: WKSP) is getting ready for pre-production of its TerraVis solar-powered tonneau cover and its extension, the standalone COR battery system. The company also revealed it is expanding its EV ecosystem with a new product termed NPEV that aims to contribute to making transportation greener. Today Worksport announced its anticipated Pre-Order platform will go live on 21ste of September.

With a physical foundation and the right partners, as it joined forces with two EV players on two upcoming electric pickups, Worksport seems ready for the next chapter of its growth story that is bound to bring new technologies to the EV table.

These updates make it clear that capacity is expanding to meet rising EV demand. In July alone, EV sales grew about 200% YoY, and approximately 5% from June.

This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure. IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you’re interested in becoming an IAM journalist contact: contributors@iamnewswire.com

Continue Reading

BenzingaEditorial

Even Covid-19 Cannot End Disney’s Enduring Magic

Published

on

Disney’s (NYSE: DIS) blowout third quarter that beat expectations across the board was fueled by growth in Disney+ subscribers and parks returning to profit. But now that Walt Disney World’s 50th anniversary is around the corner, things are looking even better.

50th anniversary celebration

Walt Disney World is gearing up for its celebration which starts on October 1. Dining is returning to Orlando, Florida park as preparations are ongoing. The fact that normal operations are resuming at parks is a good sign that the company is on track when it comes to guest and travel confidence, which translates to an improved bottom line. The party tickets are sold separately from park entry tickets which implies an exponential growth as this segment was literally crushed by the pandemic one and a half year ago. The celebration will open a busy holiday travel season so it can be assumed that Disney stands to benefit from an increase in guest spending, from large purchases like annual passes to shopping for seasonal merchandise. As for the outlook, 2022 is looking brighter for the Parks, Experiences and Products segment.

Delta variant is looming

However, Covid continues plaguing the entertainment industry and the world for more than 18 months now, and there are fears that new variants will reverse the progress at Disney’s biggest money makers as theme parks and cruise lines are its lifeblood. Box office revenue also wasn’t exempt from the devastating blowdespite management trying to reinvent the release structure to drain as much benefit as possible. Streaming also resulted in a compensation-related and public lawsuit from Scarlett Johansson who found like many of her colleagues she was severely harmed by this model.

The White House steps in

On Wednesday, U.S. President Joe Biden met with several top U.S. leaders, including the CEO of Disney, Bob Chapek, as part of his ongoing effort to push companies to require workers to be be vaccinated against COVID-19 as the delta variant rages on. Participants in the meeting also included Microsoft Corp (NASDAQ: MSFT) and Walgreens Boots Alliance Inc (NASDAQ: WBA). However, corporations such U.S. automakers General Motors Co (NYSE: GM) and Ford Motor Co (NYSE: F) are encouraging employees to get the vaccine, but they remain quiet about the executive order. The White House hopes that this meeting will serve “as a rallying cry for more businesses across the country to step up and install measures to boost vaccination rates.

Luckily for Disney that it released Disney+ when it did

Direct to consumer division that includes several streaming services besides Disney+, including ESPN+, Hulu has benefited from people being much more at home. Launched in November 2019, just a few months before the pandemic struck, Disney+  has literally kept Disney afloat while the other divisions struggled to keep their heads above water. Without this division, Disney would not have a rare bright spot over the past year and a half.

The magic lives on

Almost a century old company has endured many things, but the COVID-19 pandemic was by far the worst crisis that the entertainment giant faced as its business model was perfectly exposed to this invisible enemy. Although COVID held its cash-cows hostage, the power of Disney goes beyond the physical experience. Back in August, Target (NYSE: TGT) revealed it will nearly triple the number of Disney shops inside its stores to more than 160 by the end of year, in an attempt to increase foot traffic ahead of the anticipated holiday season. Target hopes that Disney can help it stand out and raise its toy department’s price point. Over almost a century, Disney’s brand evolved while staying loyal to its core values of its founder. In doing so, it became a synonym for storytelling that brings magic to life. Its “once upon a time” earned it an iconic status that made this global brand stronger than any virus- related fear.

This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure. IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you’re interested in becoming an IAM journalist contact: contributors@iamnewswire.com

Continue Reading

BenzingaEditorial

Oracle Is Aiming for the Cloud

Published

on

The enterprise software maker reported its fiscal first quarter revenue on Monday, with its top segment, as well as hardware, missing expectations. Revenue came below expectations as Oracle Corporation (NYSE: ORCL) announced a program during the quarter to encourage customers to adopt its public cloud services in the quarter by reducing or even eliminating its licensing support costs.

Encouraging migrations to the cloud

The support rewards program offers customers who make new commitments to buy Oracle Cloud Infrastructure services to earn rewards that can reduce or even eliminate their Oracle on-premises technology licensing support bills.

Fiscal Q1 figures

For the quarter that ended on August 31st, revenue increased 4% YoY as it amounted to $9.73 billion. Refinitiv reported analysts expected $9.77 billion, whereas the prior quarter’s growth rate was double at 8% respectively.

The two new cloud businesses

The cloud license and on-premises license segment brought in $813 million to the revenue table, down 8% and lower than the $859.7 million consensus. Cloud is fundamentally a more profitable business compared to on-premise. Management expects operating margins to be the same or better than pre-pandemic levels. The company does not disclose revenue nor operating income from its two services that now make 25% of its total revenue with an annual run rate of $10 billion.

The largest business segment, cloud services and license support, generated $7.37 billion in revenue, which is up 6%, although below the StreetAccount consensus estimate of $7.41 billion.

The hardware unit generated $763 million in revenue, down 6% and below the $778.5 million estimate.

Increased capital expenditures

Oracle’s capital expenditures exceeded $1 billion, more than doubling compared to the $436 million in the year-ago quarter as executives invested to build the necessary infrastructure to meet expected cloud demand.

To expand and strengthen its footing in the cloud computing space, Oracle, which counts Zoom Video Communications (NASDAQ:ZM) as one of its customers, has been heavily investing in opening more data centers to rent to clients as they shift their operations to the cloud.

 Fiscal Q2 guidance

For the undergoing quarter, CEO Safra Catz expects earnings per share to come in the range between $1.09 to $1.13 on 3% to 5% revenue growth. Analysts polled by Refinitiv are expecting a 5% revenue growth to result in adjusted earnings of $1.08 per share.

A crowded space

Austin, Texas-based company whose shares have risen about 40% year to date is in a crowded space of rivals no other than tech titans Microsoft Corp (NASDAQ:MSFT), Amazon.com Inc (NASDAQ:AMZN), Salesforce.com (NYSE:CRM) and IBM (NYSE:IBM) Corp that makie it much more challenging to benefit from cloud computing trends.

In a nutshell, Oracle fell short of Wall Street expectations because of incentives it offered to its customers in an attempt to position itself among the clouds.

This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure. IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you’re interested in becoming an IAM journalist contact: contributors@iamnewswire.com

Continue Reading
Advertisement

TRENDING

Advertisement

Submit an Article

Send us your details and the subject of your article and an IAM editor will be in touch with you shortly

Trending